SAN DIEGO--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced 24-month results from the two pivotal Phase III trials (RISE and RIDE) assessing the ...
Xbrane's Lucentis biosimilar, for wet AMD and other serious eye conditions, with a US launch planned for 2027.
A recent study found that the ranibizumab port delivery system (PDS) has cost-saving potential compared with regular ranibizumab or aflibercept injections for age-related macular degeneration if used ...
In the Archway study, Port Delivery System with ranibizumab (PDS) demonstrated non-inferior and equivalent visual acuity outcomes compared with monthly ranibizumab eye injections, and a favorable ...
Ranibizumab implants approved by FDA for DME offer a more convenient treatment schedule, reducing injection frequency significantly. The phase 3 Pagoda study showed noninferior visual acuity with ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
A multicenter study of 74 premature infants undergoing bedside ranibizumab injections found a 16.2 percent incidence of transient, non-severe hypoxia, with birth weight identified as the primary ...
A three-year analysis using decision tree and Markov modeling found that intravitreal ranibizumab is highly cost-effective compared with laser photocoagulation for treating retinopathy of prematurity.
Kenya's Pharmacy and Poisons Board issued a public alert warning healthcare professionals and the public about falsified Lucentis injections The fake product, bearing batch numbers 18862110 and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results